• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF'.

作者信息

Doehner Wolfram, Packer Milton

机构信息

Berlin Institute of Health-Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Department of Cardiology (Virchow Klinikum), German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

出版信息

Eur J Heart Fail. 2022 Oct;24(10):1993-1994. doi: 10.1002/ejhf.2666. Epub 2022 Sep 9.

DOI:10.1002/ejhf.2666
PMID:36036700
Abstract
摘要

相似文献

1
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF'.钠-葡萄糖协同转运蛋白2抑制剂治疗可降低射血分数降低的心力衰竭患者的血清尿酸水平——来自临床试验的经验教训。关于文章《达格列净降低尿酸浓度，尿酸是DAPA-HF中不良结局的独立预测因子》的信函
Eur J Heart Fail. 2022 Oct;24(10):1993-1994. doi: 10.1002/ejhf.2666. Epub 2022 Sep 9.
2
Reply to 'Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'.对“钠-葡萄糖协同转运蛋白2抑制剂治疗可降低射血分数降低的心力衰竭患者的血清尿酸——来自临床试验的经验教训”的回复
Eur J Heart Fail. 2022 Oct;24(10):1994. doi: 10.1002/ejhf.2686. Epub 2022 Sep 19.
3
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.达格列净对射血分数降低的心力衰竭患者生物标志物、症状和功能状态的影响：DEFINE-HF 试验。
Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16.
4
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.达格列净可降低尿酸浓度，尿酸浓度是 DAPA-HF 不良结局的独立预测因子。
Eur J Heart Fail. 2022 Jun;24(6):1066-1076. doi: 10.1002/ejhf.2433. Epub 2022 Feb 6.
5
Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?达格列净在真实世界慢性心力衰竭人群中的应用：有多少患者真正符合适应证？
Cardiology. 2021;146(2):201-206. doi: 10.1159/000512432. Epub 2021 Feb 1.
6
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
7
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.达格列净与血清钠的关系：来自DAPA-HF试验的结果
JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019. Epub 2022 Apr 6.
8
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.达格列净与沙库巴曲缬沙坦对比改善射血分数降低的糖尿病患者的预后
Am J Cardiovasc Drugs. 2022 May;22(3):325-331. doi: 10.1007/s40256-021-00506-5. Epub 2021 Oct 21.
9
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.达格列净对 2 型糖尿病心力衰竭和死亡的影响。
Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.
10
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.达格列净与射血分数降低的心力衰竭患者 2 型糖尿病发生率：来自 DAPA-HF 的探索性分析。
Diabetes Care. 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18.

引用本文的文献

1
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.钠-葡萄糖共转运蛋白 2 抑制剂在痛风患者中的临床获益。
Nat Rev Rheumatol. 2024 Apr;20(4):216-231. doi: 10.1038/s41584-024-01092-x. Epub 2024 Mar 12.